Fresh analysis spotlights cardio benefit of J&J's Invokana in diabetes patients without history of CV disease
Invokana sales may be muted, but the diabetes drug is set to get some love after its maker J&J unveiled data at the American Diabetes Association meeting on Tuesday suggesting the medicine can confer a cardiovascular benefit in patients who do not have preexisting CV disease.
Back in April, J&J had reported that in the late-stage CREDENCE study, the SGLT2 drug scored a 30% reduction in the risk of a composite of ailments: a progression to the doubling of serum creatinine, end-stage kidney disease and renal or cardiovascular death. In terms of secondary endpoints, the drug was also found be heart-protective: lowering the risk of CV death and hospitalization for heart failure by 31%, as well as major adverse CV events by 20%. In March, the company submitted an application to expand Invokana’s label to reflect its impact on chronic kidney disease.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.